<DOC>
	<DOCNO>NCT02125435</DOCNO>
	<brief_summary>The objective study ass safety , tolerability , pharmacokinetics ( PK ) single ascend intravenous ( IV ) dose ASP2408 non-elderly , healthy male female subject evaluate pharmacodynamics ASP2408 .</brief_summary>
	<brief_title>A Dose Escalation Study Assess Safety , Tolerability , Pharmacokinetics ASP2408 Following Single Intravenous Doses Healthy Subjects</brief_title>
	<detailed_description>This single-dose escalation study compose 8 sequential cohort healthy subject receive increase dos intravenously administer ASP2408 match placebo . Subjects confine clinic 8 day .</detailed_description>
	<criteria>Subject weigh least 50 kg , body mass index ( BMI ) 18.0 32.0 kg/m2 , inclusive . Results subject 's 12lead electrocardiogram ( ECG ) normal , abnormal , abnormality clinically significant determine investigator . Female subject must least two year postmenopausal OR surgically sterile ( documentation provide healthcare professional ) pregnant lactating . Male subject agrees use male condom end study 60 day post dose , whichever longer . Subject highly likely comply protocol complete study . Subject history clinically significant cardiac , endocrinologic , hematologic , hepatic , immunologic , metabolic , urologic , pulmonary , neurologic , dermatologic , psychiatric , renal , and/or major disease malignancy exclude adequately treat nonmelanoma skin cancer . Subject history severe allergic anaphylactic reaction . Subject female childbearing potential . Subject history consume 14 unit alcoholic beverage per week history alcoholism drug/chemical/ substance abuse within past 2 year ( Note : one unit = 12 ounce beer , 4 ounce wine 1 ounce spirit ) . Subject positive test alcohol drug abuse . Subject has/had symptomatic , viral , bacterial ( include upper respiratory infection ) , fungal ( noncutaneous ) infection within 1 week prior clinic checkin . Subject past history opportunistic infection . Subject supine mean systolic blood pressure &lt; 90 &gt; 160 mmHg mean diastolic blood pressure &lt; 50 &gt; 90 mmHg , mean pulse rate high 100 beat per min ( bpm ) . Subject know positive human immunodeficiency virus ( HIV ) antibody . Subject positive TB skin test Quantiferon Gold test TSPOTÂ® test Screening . Subject positive test hepatitis C antibody , positive test hepatitis B surface antigen ( HBsAg ) , positive hepatitis B core antibody . Subject 's laboratory test result : alanine aminotransferase ( ALT ) and/or aspartate aminotransferase ( AST ) , great 1.5 time upper limit normal outside normal limit consider investigator clinically significant regard remain perprotocol laboratory test . Subject receive vaccine within 60 day prior study drug administration . Subject receive systemic immunosuppressant agent within 2 month prior study drug administration . Subject previously receive antibody therapeutic biologic product prior study drug administration . Subject receive systemic steroid within 2 month steroid inhaler within 1 month prior study drug administration . Subject treatment prescription , nonprescription complementary alternative medicine ( CAM ) within 14 day prior study drug administration . Subject receive experimental agent within 30 day five halflives , whichever longer , prior study drug administration . Subject participate another clinical trial participate another dose group current trial . Subject significant blood loss , donate one unit ( 450 mL ) blood , receive transfusion blood blood product within 60 day donate plasma within 7 day prior clinic admission Day 1 . Subject history heavy smoking use tobaccocontaining product nicotine nicotinecontaining product past six month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Healthy subject</keyword>
	<keyword>ASP2408</keyword>
	<keyword>pharmacokinetics</keyword>
</DOC>